Brain Metastases, Breast Cancer, HER2-positive Breast Cancer
Conditions
Keywords
pyrotinib, brain radiotherapy
Brief summary
Brain metastases occur in 30-50% of patients with metastatic HER2-positive breast cancer. Pyrotinib is an irreversible pan-ErbB receptor tyrosine kinase inhibitor (TKI) with activity against epidermal growth factor receptor (EGFR)/HER1, HER2, and HER4. This study consists of two parts. In a phase Ib part, investigators will explore the safety and tolerance of Pyrotinib Plus Capecitabine combined with brain radiotherapy. After completing the phase Ib part, investigators will review the data and decide whether this patient is included in before the start of a phase II part. In the phase II part, investigators will evaluate the efficacy of Pyrotinib Plus Capecitabine combined with brain radiotherapy in patients with HER2 positive breast cancer patients with brain metastases.
Interventions
OTHERPyrotinib Plus Capecitabine combined with brain radiotherapy
Drug combined with radiation
Sponsors
Fudan University
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Pathologically confirmed HER2 positive advanced breast cancer 2. Age\>18 years. brain metastases confirmed by enhanced brain MRI 3. KPS≥70 4. Life expectancy of more than 12 weeks 5. Prior therapy of oral dexamethasone not exceeding 16mg/d 6. Time interval from prior therapy was more than 2 weeks, and evaluation of adverse events is no more than grade 1. 7. Maximum diameter of intracranial metastases is less than 3cm measured by enhanced brain MRI(2-3mm) 8. Prior endocrine therapy were allowed 9. Anti-Her2 targeted treatment were allowed 10. Screening laboratory values must meet the following criteria( and should be obtained within 28 days prior to registration): 1. Absolute Neutrophil Count (ANC) ≥ 1.5 x 109/L, Platelets≥ 90 x 109/L, Hemoglobin ≥ 90 g/L 2. Aspartate aminotransferase/alanine aminotransferase (AST/ALT) ≤2.5 x ULN without liver metastasis,≤ 5 x ULN with liver metastases 3. Serum BUN and creatinine ≤ 1.5 x Upper Limit of Normal (ULN) 4. LVEF ≥ 50% 5. QTcF \< 480 ms 6. INR≤1.5×ULN，APTT≤1.5×ULN 11. Signed the informed consent form prior to patient entry
Exclusion criteria
1. Leptomeningeal or hemorrhagic metastases 2. uncontrolled epilepsy 3. Severe complication: cardiovascular disease, end-stage renal disease, severe hepatic disease, infection etc. 4. Pregnancy or lactation period， women of child-bearing age who are unwilling to accept contraceptive measures. 5. Inability to complete enhanced MRI 6. Patients who are difficult or unable to be followed-up 7. Not suitable for inclusion for specific reasons judged by sponsor 8. Patients unable to swallow, with chronic diarrhea, intestinal obstruction, or multiple factors that affect drug use and absorption 9. History of allergy to pyrotinib or capetabine 10. History of immunodeficiency, including HIV positive, active HBV/HCV or other acquired, congenital immunodeficiency disease, or organ transplantation history 11. Previous use of pyrotinib combined with capetabine
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Assess safety and tolerability of Pyrotinib Plus Capecitabine combined with brain radiotherapy(Phase Ib part) | 8 weeks | AEs will be assessed according to CTCAE version 4.03. (1)Initially 3 patients will be accrued and treated with combined therapy as a lead-in safety phase. Enrollment of the study will not proceed if patients in the safety lead-in phase experience unacceptable toxicities including neurologic, hematologic and other dose limiting toxicities.(see protocol) (b)If one of initially 3 patients has experienced unacceptable toxicities, 3 more patients will be accrued . (3)If two or more patients are unable to complete radiation therapy (RT) due to toxicity related to Pyrotinib Plus Capecitabine combined with brain radiotherapy, accrual will be suspended and the study will be stopped. (4) If 3+3 patients are able to complete the treatment without unacceptable toxicities, 6 more patients will be accrued in Ib part. |
| Intracranial local tumor control rate （Phase II part) | 2 years | All intracranial progression |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Intracranial local tumor control rate with FSRT or WBRT | 2 years | Intracranial local tumor control rate |
| Intracranial Progression-Free Survival (PFS) | 2 years | Time from the date of radiotherapy to the investigator-determined date of progression (determined by RANO) or death due to any cause, whichever occurs first |
| Extracranial Progression-Free Survival (PFS) | 2 years | — |
| OS (overall survival) | 3 years | — |
Countries
China
Outcome results
None listed